Advertisements
Business

InMed Announces Results of 2021 Annual General Meeting


Article content material

VANCOUVER, British Columbia, Dec. 17, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pacesetter within the growth, manufacturing and commercialization of uncommon cannabinoids, at the moment confirmed that, at its annual basic assembly of shareholders held on December 17, 2021 (the “Meeting”), all of the issues put ahead earlier than shareholders for consideration and approval as set out in InMed’s discover of assembly and administration data round, dated October 28, 2021, have been authorized by the shareholders. In explicit, shareholders authorized the election of all director nominees to carry workplace till the subsequent annual assembly of shareholders or till their successors are elected or appointed. Results of the vote for the election of administrators on the Meeting are set out as follows:

Article content material

Director Votes For   Withheld Votes Number Percentage   Number Percentage Eric A. Adams 2,960,270 93.98%   189,717 6.02% Adam Cutler 2,980,880 94.63%   169,107 5.37% William J. Garner 2,957,803 93.90%   192,184 6.10% Andrew Hull 2,980,096 94.61%   169,891 5.39% Catherine Sazdanoff 2,902,565 92.14%   247,422 7.86%

InMed filed a report of voting outcomes on SEDAR at www.sedar.com on December 17, 2021.

About InMed: InMed Pharmaceuticals is a worldwide chief within the growth, manufacturing and commercialization of uncommon cannabinoids. Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of shopper markets, together with pharmaceutical and well being and wellness. InMed is a clinical-stage firm creating a pipeline of uncommon cannabinoid therapeutics and devoted to delivering new therapy alternate options to sufferers which will profit from cannabinoid-based pharmaceutical medication. For extra data, go to  www.inmedpharma.com and www.baymedica.com .

Article content material

Investor Contact:
Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: [email protected]

Advertisements

Edison Group:
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: [email protected] / [email protected]

Cautionary Note Regarding Forward-Looking Information:

This information launch incorporates “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) inside the that means of relevant securities legal guidelines. Forward-looking data is predicated on administration’s present expectations and beliefs and is topic to a quantity of dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements. Forward-looking data on this information launch contains statements about: being a worldwide chief within the manufacturing and growth of uncommon cannabinoids and delivering new therapy alternate options to sufferers which will profit from cannabinoid-based pharmaceutical medication.

All forward-looking data herein is certified in its entirety by this cautionary assertion, and InMed disclaims any obligation to revise or replace any such forward-looking data or to publicly announce the end result of any revisions to any of the forward-looking data contained herein to replicate future outcomes, occasions or developments, besides as required by legislation.

Advertisements

Primary Logo

Show More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button